试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
编号:NCT04965818登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:Futibatinib and Binimetinib
登记的停止原因(原文):Strategic decision by sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease
编号:NCT04984616登记状态:提前终止企业 / 申办者:Juan D. Maya
药物 / 成分:40 mg Atorvastatin/day for 120 days P.O.、Atorvastatin 80、Placebo
登记的停止原因(原文):The recruitment rate in all centers was extremely low. The number of participants failed to reach a statistically significant minimum.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
编号:NCT05005182登记状态:提前终止企业 / 申办者:Mayo Clinic
药物 / 成分:Biospecimen Collection、Bone Marrow Aspiration、Bone Marrow Biopsy、Hydroxyurea
登记的停止原因(原文):Slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
编号:NCT05048134登记状态:提前终止企业 / 申办者:Jiangsu HengRui Medicine Co., Ltd.
药物 / 成分:HRS2300、HRS2300、 SHR-1316、HRS2300、SHR-1701、HRS2300、trametinib
登记的停止原因(原文):Sponsor R\&D strategy adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
编号:NCT05094206登记状态:提前终止企业 / 申办者:Medical College of Wisconsin
药物 / 成分:0.75x10^6 cells/kg CAR20.19.22 cells、1x10^6 cells/kg CAR20.19.22 cells、2.5x10^6 cells/kg CAR20.19.22 cells、5x10^6 cells/kg CAR20.19.22 cells
登记的停止原因(原文):Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
编号:NCT05121766登记状态:提前终止企业 / 申办者:Hackensack Meridian Health
药物 / 成分:Omega-3 (EPA+DHA)、Placebo
登记的停止原因(原文):Challenges in enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Treatment of an Inherited Ventricular Arrhythmia
编号:NCT05122975登记状态:提前终止企业 / 申办者:RyCarma Therapeutics, Inc.
药物 / 成分:S48168 (ARM210)、Matching Placebo
登记的停止原因(原文):Due to challenges in recruiting patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
编号:NCT05200143登记状态:提前终止企业 / 申办者:Providence Health & Services
药物 / 成分:Ipilimumab、Nivolumab、Cabozantinib
登记的停止原因(原文):Withdrawn support from BMS.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
编号:NCT05253209登记状态:提前终止企业 / 申办者:Asklepion Pharmaceuticals, LLC
药物 / 成分:L-citrulline、Plasmalyte A
登记的停止原因(原文):Interim Analysis triggered futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
编号:NCT05280717登记状态:提前终止企业 / 申办者:Vir Biotechnology, Inc.
药物 / 成分:sotrovimab、sotrovimab、sotrovimab、sotrovimab
登记的停止原因(原文):Part C cohort 1 was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes.
查看官方原始记录 ↗